



COPY OF PAPERS
- ORIGINALLY FILED

1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

#6
5-29-02
D.L.

APPLICANT: Price, et al

§ ART UNIT:
§ 1632

FILED: June 14, 2001

§
§ EXAMINER:
§ Ton, T.

SERIAL NO.: 09/881,635

§
§
§ DOCKET: D6302

FOR: Regulation of the P21 Gene and
Uses Thereof

The Honorable Commissioner of Patents
BOX NON-FEE AMENDMENT
Washington, DC 20231

**RESPONSE TO RESTRICTION REQUIREMENT AND
CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8**


Dear Sir:

Responsive to the Restriction Requirement mailed April 26, 2002, Applicants elect Group I, claims 1-10, drawn to a method for treating or preventing a pathophysiological state of an organ in an individual, wherein said state is characterized by an undesirable level of cyclin-dependent kinase inhibitor activity in said organ, comprising the step of eliminating or reducing the expression of the *p21* gene in said organ of said individual, comprising using drug therapy, without traverse.

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Honorable Commissioner for Patents, Box Non-Fee Amendment, Washington DC 20231. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: May 9, 2002
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391
BADLER1@houston.rr.com


Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant